688065 Cathay Biotech Inc.
- 45.65
- -1.69-3.57%
Cathay Biotech Inc. News
Some Investors May Be Worried About Cathay Biotech's (SHSE:688065) Returns On Capital
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? Typically, we'll want to notice a trend of growing return on capital employed (RO
Tianjin Sitong, the shareholder of Kaisai Biotech (688065.SH), and its co-actors reduced their holdings by 4.921,000 shares
Zhitong Finance App News, Kaisai Biotech (688065.SH) issued an announcement. On May 24, 2024, the company received the “Notice Letter on the Halfway Reduction of Shares and the Progress of Shareholding Reduction” from the shareholder Tianjin Sitong Longtongyuan Enterprise Management Partnership (“Tianjin Sitong”) and its co-actor Seasource Holdings Limited (“Seasource”). As of the disclosure date of this announcement, the current holdings reduction plan has passed halfway. Tianjin Sitong and its co-actors Seasource through a major counterparty
Kaisai Biotech (688065.SH): Using centralized bidding to buy back 929,500 company shares
Gelonghui, May 6 | Cathay Biotech (688065.SH) announced that as of April 30, 2024, the company had repurchased 929,464 shares of the company through centralized bidding transactions through the Shanghai Stock Exchange trading system, accounting for 0.1593% of the company's total share capital of 583,378,039 shares. The highest price for the repurchase transaction was RMB 57.37 per share, the lowest price was RMB 38.98 per share, and the total capital paid was RMB 48,418,430.17 (excluding transaction fees such as stamp duty and transaction commissions).
Cathay Biotech Inc.'s (SHSE:688065) Biggest Owners Are Private Companies Who Got Richer After Stock Soared 18% Last Week
Key Insights Cathay Biotech's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public The top 4 shareholders own 50% of the comp
Cathay Biotech (688065.SH) announced first-quarter results, net profit of 105 million yuan, up 83.25% year-on-year
Cathay Biotech (688065.SH) disclosed its report for the first quarter of 2024. The company achieved operating revenue during the reporting period...
Shareholders of Kaisai Biotech (688065.SH) Tianjin Sitong and Seasource reduced their holdings of the company by 1.1%
Cathay Biotech (688065.SH) issued an announcement. The company received the shareholder Tianjin Sitong on April 22, 2024...
Cathay Biotech's Q1 Profit to Surge Up to 100%, Revenue to Climb 43%; Shares Up 6%
Cathay Biotech (SHA:688065) expects to book a net profit attributable to shareholders of between 94 million yuan to 115 million yuan in the first quarter, climbing up to 100.2% from the year-ago profi
Cathay Biotech Inc.'s (SHSE:688065) Price Is Out Of Tune With Earnings
When close to half the companies in China have price-to-earnings ratios (or "P/E's") below 30x, you may consider Cathay Biotech Inc. (SHSE:688065) as a stock to avoid entirely with its 59.6x P/E ratio
Kaisai Biotech (688065.SH): Shareholder Tianjin Sitong and concerted actors plan to reduce their holdings by no more than 2% in total in bulk transactions
Gelonghui, April 3, 丨 Kaisai Biotech (688065.SH) announced that according to its own financial requirements, the company's shareholder Tianjin Sitong and Seasource, the co-actor, plan to reduce their holdings of the company's shares through bulk transactions 3 trading days after the disclosure of this reduction announcement, that is, 3 months from April 11, 2024, to no more than 2% of the company's total shares (that is, 11,667,560 shares), of which: Tianjin Sitong Bulk Trading will reduce its holdings by no more than 11,167,560 shares, with a reduction ratio of no more than 1.914% of the total number of shares of the company; Seasource bulk transactions reduced
Shanxi Securities: Currently, the underlying technology of synthetic biology still has a lot of room for improvement, and product companies are easier to grow
The Zhitong Finance App learned that Shanxi Securities released a research report saying that currently there is still a lot of room for improvement in the underlying synthetic biology technology, the industry is still in the early stages of the life cycle, and product companies are more likely to grow. From a short-term perspective, product selection ability will have a critical impact on the short-term financial performance of product companies. Excellent products should have the two characteristics of “mature downstream application” and “cost leadership” to solve actual commercial needs: mature downstream applications: 1) the potential market is broad; 2) the demand is deterministic, and the market cost education is low. Cost leadership: The probability of technology implementation is high, and it has a cost advantage over existing alternative products. longterm
Does The Market Have A Low Tolerance For Cathay Biotech Inc.'s (SHSE:688065) Mixed Fundamentals?
With its stock down 15% over the past three months, it is easy to disregard Cathay Biotech (SHSE:688065). It seems that the market might have completely ignored the positive aspects of the company's
Kaisai Biotech (688065.SH): The fund-raising project “Project with an Annual Production of 500,000 Tons of Bio-based Pentanediamine and 900,000 Tons of Bio-based Polyamide” was postponed
Gelonghui, March 13, 丨 Cathay Biotech (688065.SH) announced that on March 13, 2024, the company held the 17th meeting of the 2nd board of directors and the 15th meeting of the 2nd board of supervisors to review and pass the “Proposal on the Extension of Some Fundraising Projects”, agreeing to extend the time for the fund-raising project “500,000 tons of bio-based pentanediamine and 900,000 tons of bio-based polyamide per year” to reach the intended usable state.
Kaisai Biotech (688065.SH): A total cost of 47.93 million yuan to buy back 0.1572% of the shares
Gelonghui, Feb. 29丨Cathay Biotech (688065.SH) announced that as of February 29, 2024, the company had repurchased 916,964 shares of the company through centralized bidding transactions through the Shanghai Stock Exchange trading system, accounting for 0.1572% of the company's total share capital of 583,378,039 shares. The highest price for the repurchase transaction was RMB 57.37 per share, the lowest price was RMB 45.40 per share, and the total amount of capital paid was RMB 47,930,007.80.
Investors Could Be Concerned With Cathay Biotech's (SHSE:688065) Returns On Capital
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key financial metrics. One common approach is to try and find a company with return
Cathay Biotech (688065.SH) performance report: 2023 net profit of 367 million yuan decreased by 33.66% year-on-year
Gelonghui, Feb. 23 | Cathay Biotech (688065.SH) announced its 2023 annual performance report. In 2023, the company achieved operating income of 2,114 billion yuan, a year-on-year decrease of 13.39%; realized total profit of 450 million yuan, a year-on-year decrease of 35.32%; and realized net profit attributable to owners of the parent company of 367 million yuan, a year-on-year decrease of 33.66%.
Kaisai Biotech (688065.SH)'s 180 million restricted shares will be listed and circulated on February 19
Cathay Biotech (688065.SH) announced that the total number of shares in circulation in the company's current stock listing is 180 million shares, which are listed and in circulation...
Cathay Biotech (688065.SH): Repurchase 917,000 shares as of January 31
Gelonghui, Feb. 1 | Cathay Biotech (688065.SH) announced that as of January 31, 2024, the company had repurchased 916,964 shares of the company through centralized bidding transactions through the Shanghai Stock Exchange trading system, accounting for 0.1572% of the company's total share capital of 583,378,039 shares. The highest price for the repurchase transaction was RMB 57.37 per share, the lowest price was RMB 45.40 per share, and the total capital paid was RMB 47,930,007.80 (excluding transaction fees such as stamp duty and transaction fees).
Cathay Biotech (688065.SH): Repurchase 913,800 shares through centralized bidding as of January 19
Gelonghui, January 21丨Cathay Biotech (688065.SH) announced that as of January 19, 2024, the company had repurchased 913,829 shares of the company through centralized bidding transactions through the Shanghai Stock Exchange trading system, accounting for 0.1566% of the company's total share capital of 583,378,039 shares. The highest price for the repurchase transaction was RMB 57.37 per share, the lowest price was RMB 45.95 per share, and the total capital paid was RMB 47,787,497.66 (excluding transaction fees such as stamp duty and transaction commissions).
Kaisai Biotech (688065.SH): Cumulative repurchases of 567,200 shares
Gelonghui, January 2, 丨 Cathay Biotech (688065.SH) announced that as of December 31, 2023, the company had repurchased 567,236 shares of the company through centralized bidding transactions through the Shanghai Stock Exchange trading system, accounting for 0.0972% of the company's total share capital of 583,378,039 shares. The highest price for the repurchase transaction was RMB 57.37 per share, the lowest price was RMB 51.84 per share, and the total capital paid was RMB 31,505,455.68 (excluding transaction fees such as stamp duty and transaction commissions).
Illustration丨Welcome to new technological breakthroughs! Sorting out concept stocks related to synthetic biology
According to an article published in “Nature Communications” on December 20 by researchers at the University of Southern California in the US, researchers have invented a breakthrough new technology, or completely changed the field of synthetic biology. This method, known as cloning and reprogramming and assembling natural genomic DNA (creating), provides a simpler and more cost-effective method for constructing synthetic chromosomes. It could significantly advance genetic engineering and advance medicine, biotechnology, biofuel production, and even space exploration. According to a review by Huaan Securities, synthetic biology welcomes new technological breakthroughs, and the trillion circuit may usher in a product dividend period
Analysis
Price Target
No Data
